Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Abbott Extends Change-in-Control Agreements Through 2028

Abbott Laboratories filed a Form 8-K on November 16, 2026, disclosing that on November 11, 2026, it extended its Change-in-Control Agreements with named executive officers through December 31, 2028, while Chairman and CEO Robert B. Ford's agreement will expire on December 31, 2026.

Manish Choudhary | 16 November 2026

CorMedix Files Q3 2026 Earnings Call Transcript

CorMedix Inc. filed a current report on Form 8-K on November 16, 2026, furnishing the transcript of its investor conference call held on November 12, 2026, which covered financial results for the quarter ended September 30, 2026, and also disclosed a proposed acquisition of …

Anjali Anand | 16 November 2026

Nakamoto Inc. Revises ATM Sales Agreement, Adds Two Agents

Nakamoto Inc. filed a Form 8-K on November 16, 2026, disclosing that on November 13, 2026, it amended and restated its at-the-market equity sales agreement to modify its agent roster and maintain an aggregate offering capacity of up to $4,993,570,615 in common stock.

Nitish Kishor | 16 November 2026

CorMedix Q3 2026 Earnings: $54.5M Revenue, Heron Deal

CorMedix Inc. filed soliciting material under Schedule 14A (DFAN14A) on November 16, 2026, in connection with its proposed acquisition of substantially all of the assets of Heron Therapeutics and its third quarter 2026 earnings disclosures.

Nitish Kishor | 16 November 2026

CorMedix Q3 2026 Earnings Call Transcript Filed

CorMedix Inc. filed a Form 8-K on November 16, 2026, furnishing the transcript of its investor conference call held on November 12, 2026, which discussed financial results for the quarter ended September 30, 2026, and also disclosed details related to a proposed acquisition of …

Anjali Anand | 16 November 2026

Vir Biotechnology Prices 15M-Share Offering at $10.00

Vir Biotechnology, Inc. filed a Form 8-K on November 13, 2026, disclosing an underwriting agreement dated November 12, 2026, for a public offering of 15,000,000 shares of common stock at $10.00 per share, with an expected closing date of November 16, 2026.

Anjali Anand | 16 November 2026

Powerus Files Legacy Powerus Financial Data After October Merger

Powerus Corporation filed a Form 8-K on November 13, 2026, disclosing historical and pro forma financial statements for Autonomous Power Corporation ("Legacy Powerus") following the merger completed on October 1, 2026.

Manish Choudhary | 16 November 2026

KALA BIO Granted Nasdaq Hearing Panel Listing Extension

KALA BIO, Inc. filed a Form 8-K on November 16, 2026, disclosing that a Nasdaq Hearings Panel granted the company a conditional extension to maintain its listing on The Nasdaq Capital Market following a minimum bid price deficiency notification received on August 27, 2026.

Shwetambri Chauhan | 16 November 2026

DataMEDS AI Opens ATM Offering via Dawson James Securities

DataMEDS AI, Inc. filed a Form 8-K on November 16, 2026, disclosing its entry into an at-the-market sales agreement with Dawson James Securities, Inc. to offer and sell shares of its common stock from time to time on The Nasdaq Capital Market.

Nitish Kishor | 16 November 2026

Income Opportunity Realty Investors 2026 Annual Meeting Vote Results

Income Opportunity Realty Investors, Inc. filed an 8-K with the Securities and Exchange Commission on November 13, 2026, disclosing the voting results from its Annual Meeting of Stockholders held on November 11, 2026.

Nitish Kishor | 16 November 2026
Support

Hi! How can we help you today?

Loading…